By Ross Youngs, November 25, 2025. Unveiling Hidden Microbial . . . GLP-1 [video_popup url="https://www.youtube.com/watch?v=xOv5lPKq1KQ" text="WATCH NOW"] Breaking Research: A Differentiated, Oral Approach to Weight Management is Emerging from the Microbial “Dark Matter. “Our latest white paper, “Unveiling Hidden Microbial Metabolites for Polypharmacology in Obesity Therapeutics” (Draft 2), reveals a novel, natural-product-derived scaffold with unimolecular polypharmacology—a single molecule coordinating multiple appetite
By Ross Youngs, October 31, 2025. Reversing Eroom’s Law: Finitude and Dilution in Small-Molecule Discovery Abstract Drug discovery productivity—measured as clinically viable new molecules per research has declined for decades, a trend known as Eroom’s Law. This paradox persists despite advances in screening, computing, and artificial intelligence. Here we show that it stems from two forces: the finite diversity of nature’s
By Ross Youngs, July 26, 2025 A New Paradigm for Accredited Investors: Equity vs. Direct Asset Tokenization Impact for funding under Reg D by the Newly Approved National Legislation Abstract Drug discovery productivity—measured as clinically viable new molecules per research has declined for decades, a trend known as Eroom’s Law. This paradox persists despite advances in screening, computing, and artificial
Regeneron pledges more than $1B biobucks for ModeX multispecific antibodies (Oct 22, 2025) by Darren Incorvaia. Regeneron is buying in to Modex Therapeutics’ next-generation antibody platform with a $7 million upfront payment and a total potential deal value exceeding $1 billion. The New York-based biopharma will provide binders that ModeX will pair with its platform to fashion new multispecific antibodies
